A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

← catalyst calendar

NCT07503873 · readout in 284 d

Sponsored by TG Therapeutics, Inc. (industry) · TGTX — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

350estimated

Sites

Countries

Bosnia and Herzegovina, Georgia, North Macedonia +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-01

actual

When the study began enrolling

Primary completion

2027-05-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-05-30

estimated

The whole study's end, after follow-up

First posted

2026-03-31

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Multiple Sclerosis

Interventions

Drug: Ublituximab — also filed as TG-1101
Drug: Ublituximab — also filed as TG-1101
Device: Prefilled pen

Primary outcome

what the primary-completion date above is the date OF

Part 2: Area under the curve (AUC) at Steady State [AUCss] of Ublituximab

measured Up to Week 12

Permalink · TGTX's whole pipeline · Catalyst calendar · Every registered study · What changed